Guo, Gao
Gong, Ke
Beckley, Nicole
Zhang, Yue
Yang, Xiaoyao
Chkheidze, Rati
Hatanpaa, Kimmo J.
Garzon-Muvdi, Tomas
Koduru, Prasad
Nayab, Arifa
Jenks, Jennifer http://orcid.org/0000-0002-3150-3618
Sathe, Adwait Amod
Liu, Yan
Xing, Chao http://orcid.org/0000-0002-1838-0502
Wu, Shwu-Yuan
Chiang, Cheng-Ming
Mukherjee, Bipasha
Burma, Sandeep http://orcid.org/0000-0001-7057-9845
Wohlfeld, Bryan
Patel, Toral
Mickey, Bruce
Abdullah, Kalil
Youssef, Michael
Pan, Edward
Gerber, David E.
Tian, Shulan
Sarkaria, Jann N.
McBrayer, Samuel K.
Zhao, Dawen http://orcid.org/0000-0001-6428-1698
Habib, Amyn A. http://orcid.org/0000-0003-4164-9028
Funding for this research was provided by:
U.S. Department of Veterans Affairs (2I01BX002559-08)
Foundation for the National Institutes of Health (1R01CA244212-01A1, 1R01NS119225-01A1, 1RO1CA251698, R01CA258381, R01CA246807, R01 CA194578)
Cancer Prevention and Research Institute of Texas (RP190077, RR190034)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K24CA201543-01, K22CA237752)
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors
Cancer Prevention and Research Institute of Texas
Article History
Received: 3 August 2021
Accepted: 14 June 2022
First Online: 1 August 2022
Competing interests
: The Department of Veteran’s Affairs has filed a patent (PCT/US2021/018716) on the use of tofacitinib in GBM, with A.A.H. as the inventor. The other authors declare no competing interests.